CONCORD, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, announced that Rich Gray has joined their team as the new Vice President of Business Development. Rich will leverage his 25+ years of experience leading both direct and channel sales teams to further develop channel partnerships to provide clinical interpretation on a broader scale, helping more patients gain access to more treatment options at the point of care.
“N-of-One is very fortunate to have Rich leading our sales efforts, he brings extensive experience building great sales teams in healthcare IT and in developing a comprehensive partner sales model,” said Chris Cournoyer, CEO, N-of-One, Inc. “We are confident that his leadership will be of enormous value to supporting our objectives to grow our existing relationship with Philips, Oracle, Illumina and others and at the same time extend our partnership network.”
Rich is an experienced healthcare IT veteran having served in a variety of sales, management and executive positions. Prior to joining N-of-One, Rich served in executive sales and marketing roles at such organizations as Altos Inc (now part of Flatiron Health) the IntelliDose division of IntrinsiQ (now a division of AmerisourceBergen), and Medical Systems Management (now part of Optum). Rich is a graduate of the Mass. College of Pharmacy and Health Sciences, is a Registered Pharmacist and lives in the Greater Boston area.
Through his years of leading healthcare IT sales forces, he has learned the value of strong channel partner relationships to scale businesses. “The synergistic sales relationships that strategic channel partnerships can provide is invaluable,” said Rich. “I look forward to empowering greater adoption of N-of-One’s clinical interpretation to the point-of-care for more patients.”
N-of-One is the leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. For more information, please visit www.n-of-one.com or call +1 617-202-9808.